GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference

Rhea-AI Summary

Global Blood Therapeutics (GBT) will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on June 8, 2021, at 2:10 p.m. ET. The event will be accessible via a live webcast on GBT’s website, with a replay available for one month after. GBT focuses on innovative treatments for sickle cell disease, notably the FDA-approved Oxbryta (voxelotor) and ongoing projects like inclacumab and GBT021601. The company's commitment is to transform care for underserved patient communities.

Positive

• Participation in a high-profile healthcare conference could enhance visibility and credibility.
• Live webcast may attract investor interest and engagement.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 8, 2021, at 2:10 p.m. Eastern Time.

The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next-generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com

FAQ

What time is GBT's presentation at the Goldman Sachs Healthcare Conference?

GBT's presentation is scheduled for June 8, 2021, at 2:10 p.m. Eastern Time.

Where can I watch GBT's fireside chat?

The fireside chat will be available via live webcast on GBT’s website.

What is the significance of GBT's participation in the Goldman Sachs Global Healthcare Conference?

Participation may enhance GBT's visibility and credibility in the healthcare sector.

What are some treatments developed by GBT?

GBT has developed Oxbryta, the first FDA-approved treatment for sickle cell disease, and is advancing other pipeline treatments.